Skip to main content

Table 2 Recurrence, progression and treatment failure rates of the two groups

From: Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence

 

Gemcitabine

Epirubicin or Pirarubicin

P

Recurrence

 Yes

7 (8.33%)

18 (45%)

0.000

 No

77 (91.67%)

22 (55%)

Progression

 Yes

2 (2.38%)

8 (20%)

0.001

 No

82 (97.62%)

32 (80%)

Treatment failure

 Yes

7 (8.33%)

10 (25%)

0.012

 No

77 (91.67%)

30 (75%)